CPH vs. OGI, CRDL, HLS, ACB, GUD, WEED, QIPT, DR, VHI, and SVA
Should you be buying Cipher Pharmaceuticals stock or one of its competitors? The main competitors of Cipher Pharmaceuticals include Organigram (OGI), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Canopy Growth (WEED), Quipt Home Medical (QIPT), Medical Facilities (DR), Vitalhub (VHI), and Sernova (SVA). These companies are all part of the "medical" sector.
Organigram (TSE:OGI) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
In the previous week, Organigram had 2 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 3 mentions for Organigram and 1 mentions for Cipher Pharmaceuticals. Organigram's average media sentiment score of 0.59 beat Cipher Pharmaceuticals' score of 0.24 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.
11.2% of Organigram shares are held by institutional investors. Comparatively, 1.0% of Cipher Pharmaceuticals shares are held by institutional investors. 34.7% of Organigram shares are held by company insiders. Comparatively, 44.7% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cipher Pharmaceuticals has a net margin of 96.32% compared to Cipher Pharmaceuticals' net margin of -153.80%. Organigram's return on equity of 28.19% beat Cipher Pharmaceuticals' return on equity.
Cipher Pharmaceuticals received 132 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.68% of users gave Cipher Pharmaceuticals an outperform vote while only 44.23% of users gave Organigram an outperform vote.
Cipher Pharmaceuticals has lower revenue, but higher earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Organigram presently has a consensus target price of C$3.85, indicating a potential upside of 43.66%. Cipher Pharmaceuticals has a consensus target price of C$8.00, indicating a potential downside of 9.19%. Given Cipher Pharmaceuticals' higher possible upside, research analysts clearly believe Organigram is more favorable than Cipher Pharmaceuticals.
Organigram has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Cipher Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Summary
Cipher Pharmaceuticals beats Organigram on 12 of the 18 factors compared between the two stocks.
Get Cipher Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cipher Pharmaceuticals Competitors List
Related Companies and Tools
